IL241587B - Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof - Google Patents

Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof

Info

Publication number
IL241587B
IL241587B IL241587A IL24158715A IL241587B IL 241587 B IL241587 B IL 241587B IL 241587 A IL241587 A IL 241587A IL 24158715 A IL24158715 A IL 24158715A IL 241587 B IL241587 B IL 241587B
Authority
IL
Israel
Prior art keywords
methods
pharmaceutical composition
ampk activator
serotonergic agent
serotonergic
Prior art date
Application number
IL241587A
Other languages
English (en)
Hebrew (he)
Inventor
Chen Chien-Hung
Original Assignee
Als Mountain Llc
Chien Hung Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL241587(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Als Mountain Llc, Chien Hung Chen filed Critical Als Mountain Llc
Publication of IL241587B publication Critical patent/IL241587B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
IL241587A 2013-03-15 2015-09-16 Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof IL241587B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361793407P 2013-03-15 2013-03-15
PCT/US2014/028413 WO2014144130A2 (en) 2013-03-15 2014-03-14 Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof

Publications (1)

Publication Number Publication Date
IL241587B true IL241587B (en) 2019-01-31

Family

ID=51538303

Family Applications (1)

Application Number Title Priority Date Filing Date
IL241587A IL241587B (en) 2013-03-15 2015-09-16 Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof

Country Status (16)

Country Link
US (1) US20140350064A1 (enExample)
EP (1) EP2983473A4 (enExample)
JP (1) JP2016513734A (enExample)
KR (1) KR20160005341A (enExample)
CN (1) CN105636438A (enExample)
AR (1) AR095631A1 (enExample)
AU (1) AU2014227807B2 (enExample)
BR (1) BR112015023922A2 (enExample)
CA (1) CA2909633A1 (enExample)
CL (1) CL2015002680A1 (enExample)
HK (1) HK1222297A1 (enExample)
IL (1) IL241587B (enExample)
MX (1) MX2015012760A (enExample)
RU (1) RU2015143438A (enExample)
TW (1) TW201444552A (enExample)
WO (1) WO2014144130A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180071269A1 (en) * 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
ES2567105B1 (es) * 2014-09-19 2017-02-10 Consejo Superior De Investigaciones Científicas (Csic) Derivados de indol para la prevención y/o tratamiento de diabetes ytrastornos metabólicos relacionados
WO2016126662A1 (en) * 2015-02-03 2016-08-11 Kardiatonos, Inc. Compounds for the prevention and treatment of vascular disease
WO2016200726A1 (en) * 2015-06-08 2016-12-15 Texas Tech University System Inhibitors of mci-1 as drugs to overcome resistance to braf inhibitors and mek inhibitors
KR101663543B1 (ko) * 2015-07-29 2016-10-07 고려대학교 산학협력단 부스피론 유도체 및 이를 함유하는 약학 조성물
WO2017018752A1 (ko) * 2015-07-29 2017-02-02 고려대학교 산학협력단 부스피론 유도체 및 이를 함유하는 약학 조성물
WO2017023833A1 (en) 2015-08-01 2017-02-09 Petti Stephen J Compositions and methods for combination pharmacological treatments to induce a prolonged, mild decrease in core body temperature
CN105541665A (zh) * 2016-02-18 2016-05-04 江苏大学 一种抗肿瘤药物化合物及制备方法和应用
KR101838625B1 (ko) * 2016-09-20 2018-03-14 김브라이언 아디포넥틴 수용체에 대한 작용제 펩타이드
KR20190096949A (ko) 2016-10-05 2019-08-20 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 소분자 ampk 활성화제
AU2017384392B2 (en) 2016-12-20 2023-05-25 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
AU2017384526B2 (en) 2016-12-20 2023-11-02 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
CN107252425A (zh) * 2017-07-12 2017-10-17 上海华堇生物技术有限责任公司 去氢延胡索素的药物用途
EP3713568A1 (en) * 2017-10-26 2020-09-30 Consejo Superior de Investigaciones Cientificas (CSIC) Combination product for the treatment of neurological and/or psychiatric disorders
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof
US11208475B1 (en) * 2018-01-30 2021-12-28 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators
CN108159044A (zh) * 2018-02-26 2018-06-15 华中科技大学 抗坏血酸与二甲双胍的复合制剂用于制备化疗药物的应用
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN111892516A (zh) * 2018-08-08 2020-11-06 中国人民解放军总医院 抗肿瘤化合物
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN109771424B (zh) * 2019-03-11 2021-03-16 马慧 一种防治老年ⅱ型糖尿病性骨质疏松症的药物组合物及其应用
CN109793727A (zh) * 2019-03-13 2019-05-24 湖北科技学院 一种有效抗恶性肿瘤的药物组合物及其应用
EP4027987A4 (en) 2019-09-10 2023-11-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods and materials for increasing level of phosphorylated ampk protein
CN110559298A (zh) * 2019-10-28 2019-12-13 中国药科大学 一种天然化合物Egenine用于制备抗肾纤维化药物的用途
CN115667217A (zh) 2020-05-19 2023-01-31 赛本爱尔兰有限公司 氘化的色胺衍生物和使用方法
WO2022017440A1 (zh) * 2020-07-22 2022-01-27 山东绿叶制药有限公司 5-ht 2a受体抑制剂或反向激动剂及其制备方法和应用
CR20230467A (es) * 2021-03-10 2024-02-20 Jnana Therapeutics Inc Inhibidores de molécula pequeña de la función de slc6a19 de mamífero
JP2024527574A (ja) 2021-07-07 2024-07-25 テラン バイオサイエンシズ インコーポレイテッド Ｎ，ｎ－ジメチルトリプタミン及び関連する幻覚剤ならびにその使用
CA3237988A1 (en) 2021-11-12 2023-05-19 Terran Biosciences Inc. Psilocybin and o-acetylpsilocin, salts and solid state forms thereof
KR20250164151A (ko) * 2022-12-05 2025-11-24 엔베다 테라퓨틱스, 인크. 소양증의 치료를 위한 누트카톤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US20070244202A1 (en) * 2004-06-28 2007-10-18 Kao Corporation Ampk Activator
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US7754700B2 (en) * 2006-04-24 2010-07-13 Trager Seymour F Composition and methods for alleviating symptoms of neurotoxicity
US20120183600A1 (en) * 2007-01-16 2012-07-19 Chien-Hung Chen Novel composition for treating metabolic syndrome and other conditions
RU2486902C2 (ru) * 2007-01-16 2013-07-10 АЙПИИНТЛ, ЭлЭлСи Новая композиция для лечения метаболического синдрома
WO2011112167A1 (en) * 2009-03-13 2011-09-15 Reset Therapeutics, Inc. Compositions and methods for diabetes treatment
US8486922B2 (en) * 2010-04-28 2013-07-16 Chien-Hung Chen Composition

Also Published As

Publication number Publication date
HK1222297A1 (zh) 2017-06-30
CN105636438A (zh) 2016-06-01
MX2015012760A (es) 2016-06-17
KR20160005341A (ko) 2016-01-14
EP2983473A4 (en) 2016-11-23
JP2016513734A (ja) 2016-05-16
CA2909633A1 (en) 2014-09-18
WO2014144130A2 (en) 2014-09-18
WO2014144130A3 (en) 2015-02-05
TW201444552A (zh) 2014-12-01
BR112015023922A2 (pt) 2017-07-18
EP2983473A2 (en) 2016-02-17
CL2015002680A1 (es) 2016-09-02
AU2014227807A1 (en) 2015-11-05
US20140350064A1 (en) 2014-11-27
RU2015143438A (ru) 2017-04-21
AR095631A1 (es) 2015-10-28
AU2014227807B2 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
IL241587B (en) Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof
TWI560180B (en) Substituted benzamides and methods of use thereof
ZA201506984B (en) Microarray for delivery of therapeutic agent and methods of use
ZA201602948B (en) Compositions comprising a defined microbiome and methods of use thereof
SI3932932T1 (sl) Nevroaktivni steroidi in postopki za uporabo le-teh
ZA201601701B (en) Inhibitors of erk and methods of use
IL234884A0 (en) Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
EP2973253A4 (en) Integrated modular health platforms and methods of use
IL240729A0 (en) Solid compounds containing glucodinase activator, methods for their preparation, and their use
IL244066A0 (en) Triazolopyridine compounds, preparations and methods for their use
SMT202400191T1 (it) Composizione di inibitore di IL-1Beta e uso di essa
EP3049389A4 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP3074028A4 (en) Activity enhancing curcumin compositions and methods of use
IL240505A0 (en) Accumulations of lanthanides and methods for their use
EP3049077A4 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
GB201301979D0 (en) New composition and use thereof
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
LT3024825T (lt) Imidazolo karboksamidai ir jų panaudojimas kaip faah inhibitorių
GB201518035D0 (en) Prebiotic composition and method of its use
IL239872A0 (en) Metriptase inhibitors and pharmaceutical preparations containing them
GB201518882D0 (en) Agrochemical composition and method of use thereof
TH1501005528A (th) องค์ประกอบทางเภสัชกรรมที่ประกอบรวมด้วย ampk แอกติเวเตอร์ และซีโรโทเนอร์จิกเอเจนต์ และวิธีการใช้ของสิ่งนี้
GB201310349D0 (en) Composition and method of use thereof
GB201301928D0 (en) Composition and method of use thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees